874-37-3

Usage

Uses

Used in Organic Synthesis:
2,1,3-Benzothiadiazol-5-amine is used as a building block in organic synthesis for its unique structural and functional properties, contributing to the development of novel compounds with diverse applications.
Used in Functional Materials:
2,1,3-Benzothiadiazol-5-amine is used as a component in functional materials for its thermal, photophysical, and electrochemical properties, enhancing the performance of materials in various industries.
Used in Biological Systems:
2,1,3-Benzothiadiazol-5-amine is used in biological systems for its potential role in the development of new pharmaceuticals and bioactive compounds, although further research is required to fully understand its interactions and effects within biological contexts.
Note: The specific applications in different industries are not provided in the materials. The uses listed above are general applications based on the compound's properties and potential. Further research and development may reveal more specific applications in various industries.

InChI:InChI=1/C6H5N3S/c7-4-1-2-5-6(3-4)9-10-8-5/h1-3H,7H2

Upstream product

• 99-56-9 4-Nitrophenylene-1,2-diamine 
• 21110-91-8 5-acetamidobenzo-2,1,3-thiadiazole 
• 768-10-5 benzo[1,2,5]thiadiazol-5-ol 
• 273-13-2 benzo[1,2,5]thiadiazole 
• 16252-88-3 5-nitro-2,1,3-benzothiadiazole 

Downstream Products

• 21110-91-8 5-acetamidobenzo-2,1,3-thiadiazole 
• 182012-46-0 4-nitro-benzenesulfonic acid benzo[1,2,5]thiadiazol-5-ylamide 
• 768-10-5 benzo[1,2,5]thiadiazol-5-ol 
• 30536-22-2 5-amino-4-nitrobenzo[1,2,5]thiadiazole 
• 1711-66-6 benzo[1,2,5]thiadiazole-4,5-diamine 
• 100191-31-9 6-chloro-benzo[1,2,5]thiadiazol-5-ylamine 
• 944447-41-0 2-(2,1,3-benzothiadiazol-5-ylamino)-8-cyclopentyl-6-(2,6-dichlorophenyl)-8H-pyrido[2,3-d]pyrimidin-7-one 
• 944447-82-9 C₂₈H₂₆Cl₂N₆OSSi 
• 944447-37-4 2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one 
• 918106-11-3 N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea 
• 211-33-6 Thiazolo<5,4-e>benz-2,1,3-thiadiazole 
• 2564-38-7 6H-thiazolo[5',4':3,4]benzo[1,2-c][1,2,5]thiadiazole-7-thione 
• 2518-38-9 2-Methyl-thiazolo-<4.5-g>-benz-2.1.3-thiodiazol 
• 182012-50-6 sulfanilic acid benzo[1,2,5]thiadiazol-5-ylamide 

Relevant academic research and scientific papers

Benzothiadiazole compound and preparation method and use thereof

The present invention relates to a benzothiadiazole compound represented by the following formula I, and a preparation method and use thereof, the benzothiadiazole compound has the biological activityof inhibiting protein-tyrosine-phosphatase SHP2, can be used as a tool compound to study the biological functional relevance of the protein-tyrosine-phosphatase SHP2 in a cell signal transduction process, and provides a new means for prevention and treatment of cancer and metabolic and immune diseases.

A practical and chemoselective reduction of nitroarenes to anilines using activated iron

Reduction of nitroarenes to anilines using activated iron generated by Fe/HCl or Zn/FeSO4 is described. A variety of functional groups such as alkyne, ketone, enone, nitrile, lactone, and aromatic halide are well tolerated under these conditions.

Pyrazole compounds

Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

N-heteroaryl aryl-substituted thienyl-furyl-and pyrrolyl-sulfonamides and derviatives thereof that modulate the activity of endothelin

Thienyl-, furyl- and pyrrolyl-sulfonamides, formulations of pharmaceutically-acceptable salts thereof and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides, formulations thereof and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit the activity of endothelin are also provided.

FRIES REACTION AND DAKIN REARRANGEMENT IN BENZO-2,1,3-THIADIAZOLES

The Fries rearrangement of 4- and 5-acetoxybenzo-2,1,3-thiadiazoles has given 4-hydroxy-7-acetyl- and 5-hydroxy-4-acetylbenzo-2,1,3-thiadiazoles, which on oxidation afford mixtures of 5-chloro-4,7-dioxo- and 5,6-dichloro-4,7-dioxobenzo-2,1,3-thiadiazole and of 6-chloro-4,5-dioxo- and 6,7-dichloro-4,5-dioxobenzo-2,1,3-thiadiazole.Reaction of 6,7-dichloro-4,5-dioxobenzo-2,1,3-thiadiazole with ortho-phenylenediamine gives 4,5-dichloro-2,1,3-thiadiazolophenazine.